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Using contrast-enhanced computed tomography, the ef-
fects of hyperosmolar mannitol and methylprednisolone 
on experimentally produced myocardial infarcts were 
evaluated serially over the course of approximately I 
month. Infarct size, initial perfusion defect (jeopardized 
segment) and noninfarcted muscle mass were deter-
mined in three groups of conditioned mongrel dogs. Group 
I (n = II) served as the control group, groups 2 and 3 
were pretreated with mannitol (375 mg/kg, n = 10) or 
methylprednisolone (7.5 mg/kg, n = II). Each animal 
in the treatment groups was treated with identical doses 
of the originally administered agent twice daily for 7 
days after coronary occlusion. Each group developed 
increases in the non infarcted muscle mass of the left 
ventricle (compensatory hypertrophy). The mean in-
crease averaged more than 20% over 30 days when all 
groups were included together. Infarct size was smaller 
The importance of myocardial infarct size in patients with 
acute ischemic damage has been previously demonstrated 
(1,2). Rude et at. (3) recently reviewed many of the agents 
thought to be of value in infarct size reduction. These studies 
were limited by the nature of techniques utilized for esti-
mating infarct size. the lack of knowledge of the natural 
progression of infarct size in vivo and the uncertainty be-
tween short- and long-term infarct size modifications. 
Contrast-enhanced computed tomography has been shown 
to accurately quantitate myocardial infarct size (4-11). These 
studies examined the ability of computed tomography to 
detect and quantitate the size of myocardial infarcts in ex 
vivo and in vivo experimental models and in acute. chronic 
From the San Diego Veterans Administration Medical Center and the 
Department of Radiology, University of California Medical Center. San 
Diego, California. This study was supported in part by the Research Service 
of the Veterans Administration. the Technicare Corporation (Cleveland, 
Ohio) and funds from the Society of Nuclear Medicine (Tetalman Memorial 
Award, New York. New York) and the Association of University Ra-
diologish (Herhert M. Stauffer Award, Washington. D.C.) awarded to Dr. 
Slutsky. Manuscript received May 14. 19X4: revi,ed manu,cript rcccivcu 
luly 30. 19X4, accepted August 22. 1984. 
Auure,," for reprint-.: Rohert A Slutsky, MD. University of California 
(H-755). 225 Dickinson Street. San Diego, California 92J(l.'. 
'<', 19X5 hy the American Collc~e 01 Caruiology 
in both of the treatment groups. However, at 4 days 
after infarction, mannitol-treated dogs had a mean in-
farct size that was 68 ± 8% (± standard error of the 
mean) of the size of control infarcts (p < 0.01) and 
methylprednisolone-treated dogs had a mean infarct size 
that was 77 ± 6% of the size of control infarcts (p < 
0.(1) (referenced to the initial perfusion defect). At 30 
days, these differences were less substantial (though still 
significant), 88 ± 4% and 85 ± 5%, respectively. 
Pharmacologic interventions can be shown to alter 
the size of an acute myocardial infarction, particularly 
when examined over the time course of infarct healing. 
Importantly, transient reduction in myocardial water 
content in the first several days after infarction may 
result in an overestimation of the therapeutic utility of 
the intervention. 
(J Am Coli Cardiol /985;5:273-9) 
and reperfused myocardial infarction (8-11). In addition, 
we OS) recently studied dogs serially over the course of I 
month after occlusion of the left anterior descending coro-
nary artery using contrast-enhanced computed tomography. 
Scans were obtained acutely (20 minutes after occlusion) 
and then at multiple time periods until sacrifice approxi-
mately I month later. We found that infarct size increased 
at 4 days when compared with the initial perfusion defect 
( + 65 ± 20%, ± standard error of the mean [SEM)), then 
progressively decreased. The initial perfusion defect over-
estimated the eventual infarct size at I month by 33 ± 15%. 
Noninfarcted left ventricular muscle mass increased signif-
icantly (27 ± 7% greater at I month compared with day 
0) over time. presumably representing compensatory left 
ventricular hypertrophy. The left ventricular muscle mass 
at necropsy correlated well (r = 0.94, P < 0.001) with the 
mass calculated using tomography immediately before 
sacrifice. 
The purposes of the current studies were to evaluate the 
effects of hyperosmolar mannitol and methylprednisolone 
on tomographic estimates of infarct size over time, to ex-
amine the associated changes in compensatory hypertrophy 
of the non infarcted residual muscle and to relate the short-
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term changes in infarct size in each treatment group with 
bulk water content in the infarct zone. 
Methods 
Study J 
Experimental model. The experiments were conducted 
in conditioned mongrel dogs weighing 22 to 35 kg. Each 
animal was anesthetized with intravenous sodium pen to-
barbitol (25 mg/kg) before left thoracotomy. A hydraulic 
occluder was placed around the proximal left anterior de-
scending coronary artery. The catheter was burrowed sub-
cutaneously and externalized. An injection catheter was placed 
into the right atrium and also burrowed subcutaneously. The 
wound was aseptically closed and the dogs were allowed to 
recover. Control scans were obtained 4 to 7 days after sur-
gery in all animals to ensure that none developed infarction 
during the preparation of the initial experimental model. In 
addition, enzymatic analysis during the first 24 to 48 hours 
after the preparation confirmed the later tomographic data. 
Three or more days after the control scans were obtained, 
each animal was premedicated with subcutaneous morphine 
sulfate (2.5 to 3.0 mg/kg) and intramuscular procainamide 
(150 mg). They were taken to the scanner and anesthetized 
with sodium pentobarbital (25 mg/kg) intravenously. par-
alyzed with succinylcholine (1.0 to 1.5 mg/kg) intrave-
nously and ventilated with a Harvard respirator (14 to 16 
breaths/min. tidal volume 12 to 15 cc/kg). The hydraulic 
occluder was inflated with the animal in the scanner. The 
dogs were scanned immediately after coronary occlusion 
and then at 3 to 4 days. 7 to II days and 28 to 32 days 
after occlusion. After the final scan. the animals were sac-
rificed and postmortem examinations were performed. 
Treatment groups. The dogs were randomly divided into 
three groups. Group I served as a control group, group 2 
was given hypertonic mannitol (375 mg/kg intravenously) 
(25% solution, Abbott Laboratories) immediately before and 
then twice daily for 7 days after occlusion (3 cc/min for 15 
to 22 minutes) and group 3 received 7.5 mg/kg of intra-
venous methylprednisolone sodium succinate (Elkins-Sinn, 
Inc.) just before and then twice daily for 7 days after oc-
clusion. In three dogs, we assessed the dose of mannitol 
used in this study on short-term measures of osmolality 
(Advanced Instruments, Inc.). Osmolality increased from a 
mean of 294 ± II to 327 ± 14 mosmol. Measurements 
were performed just before and then 5 minutes after infu-
sion. In two dogs, methylprednisolone was found to have 
no effect on osmolality. Thirty-two dogs survived for the 
duration of the experiment (II in group I, II in group 2 
and 10 in group 3) and were used for evaluation of the 
study. 
Computed transmission tomographic analyses. All 
studies were performed on a Technicare 2020 whole body 
scanner. with an individual scan time of 2 seconds. The 
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scanning technique was set at 120 kYp, 100 mA, 10 mm 
slice thickness and a 25 cm scanning circle. The scanner 
has 720 stationary detectors. All images were reconstructed 
utilizing the same reconstruction algorithm with a 512 x 
512 matrix. 
On the day of infarction, after a bolus of 40 ml, an 
intravenous infusion of meglumine sodium diatrizoate (76%) 
was started 20 minutes after occlusion of the left anterior 
descending coronary artery at a rate of 6 cc/min (lasting for 
10 minutes, total volume = 100 m!) using a Harvard in-
fusion pump. For orientation purposes, a set of (ungated) 
scans was obtained from the apex to the base of the left 
ventricle (perpendicular to the long axis of the ventricle) at 
10 minutes into the infusion period. The contrast infusion 
was then stopped. Ten to 15 minutes after cessation of the 
contrast infusion, a series of ungated scans was again ob-
tained from the apex to the base of the heart. On every scan 
day thereafter, the same protocol was followed. All scans 
were obtained during held inspiration. The scans taken dur-
ing the infusion of contrast medium on the day of occlusion 
were used to quantify the perfusion defect, whereas the scans 
obtained on subsequent days were used to quantify the con-
trast enhancement of the infarct itself and to quantitate in-
farct size. 
Postmortem examination. One day after the final scans, 
each animal was sacrificed and the heart removed and sec-
tioned at I cm intervals from the apex to base of the left 
ventricle along the major axis. The slices were incubated 
in a I % solution of triphenyltetrazolium chloride (Sigma 
Chemicals) in phosphate buffer for 10 minutes at 37°C (12,13). 
The endocardial and epicardial borders of the left ventricular 
wall and the visible area of infarction were traced onto clear 
film overlays. These overlays were analyzed as follows. 
Data analysis. Infarct size measurement. Each set of 
images (apex to base) was printed on transparent film along 
with spatial calibration markers. In each animal. on scans 
obtained on the initial occlusion day, one region from each 
slice was defined as the "perfusion defect." This consisted 
of an area of lower attenuation compared with the normally 
enhancing myocardium on images obtained after the infu-
sion of contrast medium. On the scans obtained on later 
days, a second region in addition to the area of low atten-
uation was defined as the "enhanced defect," which rep-
resented the area of myocardium demarcated by the outer 
margin of a region of delayed contrast enhancement at the 
periphery of the infarct zone. On delayed scans, the pe-
riphery of the infarct has greater enhancement than the nor-
mal myocardium and center of the infarct. This region of 
delayed enhancement corresponds to the region of accu-
mulation of technetium-99m pyrophosphate in hearts with 
infarction (14). Higgins et al. (14) showed that contrast 
material is a marker of myocardial nerosis and that its dis-
tribution depends on residual flow. Thus, enhancement and 
the low attenuation defect when summed (days after injury) 
better reflect infarct size than does the perfusion defect alone. 
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In addition, we have found (9) that the contrast-enhanced 
infarct estimate correlates better with the infarct size than 
does the perfusion defect alone. In our experience, the best 
representation of this was on the ungated images obtained 
at 10 minutes after cessation of the infusion (20 minutes 
from the start of the contrast infusion). 
Volume of the jeopardized and infarcted reKions of'the 
left ventricle was determined by planimetry utilizing a Hew-
lett-Packard computer/digitizer (9825/9874A) system, with 
manual tracing of the "'perfusion defect" and "'enhanced 
defects," respectively. The computer then calculated the 
volume of the images obtained by planimetry. The ventric-
ular slices were each assumed to be cylindrical. The volume 
of the computed tomographic calculated defect (either initial 
"'perfusion" defect or "enhanced" infarct) was obtained 
by summing the volume of the perfusion defect or infarct 
(each slice was I cm) for each slice from the apex to the 
base of the heart. The postmortem overlays were similarly 
determined by planimetry and the same geometric assump-
tions were made. We found that infarct size from tomog-
raphy correlated well with postmortem values for all of the 
animals entered into the first portion of the study (r = 0.92, 
SEE ±2.0 g). 
In six dOKs. we assessed the relation between the per-
fusion defect determined by computed X-ray transmission 
tomoKraphv and that determined by thallium scintiKraphv. 
These animals were anesthetized and underwent left anterior 
descending coronary artery occlusion in the scanner. Ten 
minutes after occlusion. I to 1.5 mCi of thallium-20 I was 
administered intravenously. Ten minutes later. contrast me-
dium was administered as an infusion (identical to the tech-
nique in the present study), and cross-sectional scans of I 
cm in depth were obtained. The vertical axis of the scans 
were aligned with the long axis of the left ventricle. Images 
were obtained from the apex to the base of the heart. Once 
the scans were reconstructed. the animals were killed with 
intravenous potassium chloride. The hearts were rcmoved 
and sectioned (I cm depth) along the long axis of the left 
ventricle (analogous to the X-ray film image acquisition). 
Each postmortem section was imaged with a standard gamma 
camera peaked and windowed for thallium-20 I. Both the 
X-ray and radionuclide (ungated) images were printed on 
transparent film along with spatial calibration markers. In 
each animal, the perfusion defect was subjected to plani-
metry (region of reduced attenuation on tomograms or re-
duced radionuclide emissions on thallium scintigrams). The 
volumes from tomographic and radionuclide data were ob-
tained by summing the cross-sectional volumes (each slice 
was I cm, and the geometry of each section was assumed 
to be cylindrical) from the apex to base of the heart. The 
perfusion data from both techniques correlated well (r = 
0.96, P < 0.01). 
The variability of this technique in our laboratory when 
the slices are retraced and redigitized is ± 3.5% ( 10). More-
over, when each scan is retraced and analyzed by a second 
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observer unaware of the previous finding, the coefficient of 
variation is within yl/C. 
Le/t I'ellfricular mass estimate. The volume of left ven-
tricular myocardial mass was also calculated from the un-
gated images and the postmortem overlays. This was ac-
complished by using planimetry to measure the left ventricular 
myocardium from the apex to the level of the left ventricular 
outflow tract as previously described (In. The total left ven-
tricular mass derived from X-ray tomography correlated 
well with postmortem values in the present study (r = 0.94, 
n = 32). Similar values have been previously reported by 
others (15). Noninfarcted mass was derived by subtracting 
infarct mass from total mass. The infarct volume was then 
divided by the volume of left ventricular mass yielding a 
percent of myocardium that was infarcted. All myocardial 
measurements were converted to mass assuming a density 
of 1.05 g/cm'. 
The relation between the initial perfusion defect, anal-
ogous to an area of jeopardy, and the subsequent volume 
of calculated infarction was analyzed over time by the ratio: 
Infarct jeopardy ratio 
Volume of enhanced defect 
Volume of perfusion defect 
This calculation was made for each sampling point during 
the study. 
Stud\' 2 
In an additional 18 dogs, the identical surgical protocol 
was followed. Three groups were again identified (n = 6 
in each group), and control and therapy groups were defined. 
Unlike the initial study, each animal was sacrificed 4 days 
after the occlusion of the left anterior descending artery. 
Once aKain a perfusion zone was determined immediately 
alter coronarv occlusion. At postmortem examination, the 
infarct zone was easily visualized without staining and five 
to six transmural samples of approximately I cc volume 
were taken from the normal and infarct segments. Before 
samples were removed, the heart was sectioned and sub-
jected to planimetry to obtain calculated infarct zone as a 
percent of total muscle mass. 
Three core samples were also taken from within normal 
and in/clrcted mY0('(lrdium (but not including either the edge 
of the regions or the edge of the heart) from the animals 
with 30 days of infarction (study I) just before staining 
(from within an infarct zone to limit distortion of infarct 
size correlation). These samples were handled in the iden-
tical manner of the preceding samples. 
The samples were weighed (Mettlars beam balance), gently 
dried for 7 days in a vacuum oven and reweighed. The water 
content of the infarct tissue <I wet weight - dry weight I/wet 
weight) was then normalized to the values derived from 
control segments of myocardium from the noninfarct zone. 
Y
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Table I. Size of Initial Perfusion Defect 
Dc fcctiTotal 
Defect (g) Left Ventricular Mass ('if) 
Group I 
(control) 
Group 2 
(mannitol) 
Group 3 
(mcthylprednisolone) 
16.9 ± 2.2 21.4 ± 2.1 
16.6 ± 2.4 20.9 ± 1.7 
17.4 ± 2.1 22.4 ± 2.1 
Statistics. All data are given as a group mean ± I 
standard error of the mean. Repeated measures analysis of 
variance was used to evaluate all raw data over time (16). 
The correlations of the final X-ray tomographic infarct size 
and total left ventricular mass with the pathologic specimen 
were obtained with a least squares fit using linear regression 
analysis and are provided in the Methods section. Groups 
were compared at the same point in time using standard 
analysis of variance. 
Results 
Acute hemodynamics. After coronary occlusion, hy-
perosmolar mannitol and methylprednisolone resulted in no 
significant change in mean left atrial pressure (3.1 ± 1.0, 
2.7 ± 1.5 and 2.9 ± 2.4 mm Hg, groups I, 2 and 3, 
respectively), and no significant change in heart rate or mean 
arterial pressure. 
Initial and subsequent infarct size (Tables I and 2). The 
initial perfusion defects were similar in each group, and 
each perfusion defect represented a consistent proportion of 
the total left ventricular mass (Table I). The serial changes 
in infarct size from each group are shown in Table 2 and 
Table 2. Serial Infarct Size Changes 
Day 0 
lACC Vol. 5. No.2 
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presented as a percent of noninfarcted mass and as a ratio 
with the initial perfusion defect. At 4 days, the .. infarct 
jeopardy" ratio (infarct/perfusion defect) was progressively 
smaller when comparing control dogs with methylpredni-
solone- and mannitol-treated dogs. The difference was min-
imized as time passed. The 4 day infarct size difference 
(difference in the ratio of infarct size to initial perfusion 
defect between the groups) was 68 ± 8% of control for the 
mannitol group and 77 ± 9% of control for the methyl-
prednisolone group (both p < 0.01). At 30 days, these 
values were only 88 ± 4 and 85 ± 5%, respectively (both 
p < 0.05). These differences were not apparent when ex-
pressed as a percent of total left ventricular mass. In part, 
this reflects differences in the amount of compensatory hy-
pertrophy in the steroid-treated group and small differences 
in the initial perfusion defects among the groups. 
Myocardial infarct water content (Table 3). When the 
second group of dogs with a 4 day infarct were evaluated, 
the size of the infarct jeopardy zone (at day 4) appeared to 
be related to water content in groups I, 2 and 3. The linear 
correlation between infarct jeopardy zone ratio and water 
content ratio was good for the combined treatment groups 
(r = 0.88, P < 0.005). The 30 day infarct samples had 
similar water content in the infarct zone, suggesting that 
infarct salvage was not solely a manifestation of myocardial 
swelling. 
Development of compensatory hypertrophy (Table 4). 
Each treatment group developed compensatory hyper-
trophy by I month after initial infarction. The dogs that 
received methylprednisolone (group 3) developed less com-
pensatory hypertrophy than the animals in group I (control) 
or 2 (hypertonic mannitol). Because infarct size was similar 
in groups 2 and 3, it appears that methylprednisolone may 
limit the development of hypertrophy in animals after ex-
perimental infarction. Finally, the correlation of postmortem 
Day 4 Day 9 Day 30 
Percent Left Ventricular Mass 
Group I 
(control) 
Group 1 
(mannitol) 
Group 3 
(mcthylprednisolone) 
Group I 
(control) 
Group 2 
(mannitol) 
Group 3 
(mcthylprednisolone) 
21.4 ± 1.1 
20.9 ± 1.7 
22.4 ± 2.1 
1.00 ± 0.00 
1.00 ± 0.00 
1.00 ± 0.00 
*p < 0.0 I versus group I; tp < 0.05 versus group I. 
30.0 ± 3.21 19.9 ± 3.1 12.7 ± 1.4 
22.3 ± 2.9' 17.1 ± IXr 10.9 ± 2.0 
15.0 ± 1.9" 19.4 ± I.'tl· 11.4 ± 1.4 
Infarct Jeopardy Ratio 
1.62 ± 0.22 1.05 ± 0.11 O.6X ± 0.05 
1.10 ± 0.10'· (l.X7 0: O.J5"1" 0.60 ± 0.06"!" 
1.24 ± 0.191· 0.94 ± 0.16"!" 0.5X ± 0.07"1 
t
t
t
e !
e
l
l
2
e
2
2
2
:±: l 2
e
:±:
"
'
:±:
O.2 i
0.
O. i
O.O7"!
lACC Vol. 5. No.2 
February 19H5:273-9 
SLUTSK Y AND MURRAY 
MODIFICATION OF INFARCT SIZE 
277 
Table 3. Water Content ('Ic) of Infarct Segmcnh 
Normal Infarct Ratio 
4 Day Infarch 
Group I 
(control) 
Group 2 
(mannitol) 
Group 3 
(methylprednisolone) 
755 
75.3 
76.0 
, 05 
t 04 
I 0,4 
X4.4 ± 1.2 I 12 + 0.02 
79.0 t- 1.4 1.05 t- 0.04 
X2.0 ± 0.6 I.OX ± (Un 
,\0 Day Infarch 
Group I 
(control) 
Group 2 
(mannitol) 
Group 3 
(methylprednisolone) 
75.9 t O.X 
75 . .1 + I I 
76.1 t 07 
and computed tomographic infarct size estimates was ex-
cellent (r = 0.92, SEE ± 0.5 g). 
Discussion 
Because few studies directed at evaluating the change in 
myocardial infarction size are available (X) and the reduction 
of infarct size is an important goal in the clinical manage-
ment of acute ischemic injury (17), this study was devised 
to examine the effects of agents that limit inflammatory 
reactions and edema formation on the natural progress of 
infarct size and compensatory hypertrophy. U ngated con-
trast-enhanced computed tomography for infarct size eval-
uation has been repeatedly validated in this and other lah-
oratories in experimental canine infarction (4-11 ). 
Effects of acute ischemic injury. The development of 
cell swelling and tissue edema after ischemic injury has 
74,4 + 0.9 O.9X t (l.06 
74.0 ± 07 09Xt 0.10 
74.9 ± O.X O.9X + 0 II 
been repeatedly reported in myocardial tissue as well as in 
other tissues (I X-23). Many studies (I X,21-26) have shown 
that altered membrane permeability and deranged cell vol-
ume regulation are directly involved with and contribute to 
ischemic myocardial injury. From these observations, re-
ductions in infarct size have been reported with hypertonic 
materials thought to reduce intracellular volume 
(I X, 19.22.27). Although wc also noted these changes, we 
were ahle to document only a small reduction in infarct 
volume once the region of ischemic injury was no longer 
edematous. Antiinflammatory agents are thought to limit 
infarct size by reduction of cell swelling and inhibition of 
the inflammatory response to tissue injury (2X,29). They 
may also stabilize lysosomal membranes and augment col-
lateral myocardial hlood flow (3,20). Although a series of 
studies (3) have reported heneficial effects of corticosteroids 
Table 4. Analysis of Compensatory Hypertrophy of Noninfarcted Muscle 
Group I 
(control) 
Group 2 
(mannitol) 
Group 3 
(methylprednisolone) 
Group I 
(control) 
Group 2 
(mannitol) 
Group 3 
(methylprednisolone) 
o Days 4 Days 
Percent Initial Total Muscle Mass 
78.6 ± 3.9 XO.6 ± 4.2 
79.1 ± 4.9 80.6 ± 5.5 
77.3 ± 5.8 81.5 ± 4.4 
Percent Change Versus Initial 
2.5 :+: 1.7 
1.9 :+: 2.0 
S.O :+: 4.X 
*p < 0.01 versus day 0; tp < 0.005 versus day 0; :j:p < 0.05 versus groups I and 2. 
9 Days 33 Days 
90.2 ± 5.1* 95.9 ± 5.7t 
88.0 ± 5.0* 95.9 ± 5.9t 
87.4 ± 4.1* 91.8 ± 4.7+ 
14.X ± 4.3 22.0 ± 4.7 
IU:+: 5.0 21.2 ± 4.0 
12.6 ± 4.7 IX.8 ± 4.8+ 
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on infarct size and prognosis, exacerbation of aneurysm 
development, thinning of scar formation and reduction in 
infarct healing have also been reported. 
Effects of mannitol and methylprednisolone on in-
farct size. In the current study, both mannitol and meth-
ylprednisolone slightly, though significantly, reduced ulti-
mate infarct size when compared with the initial zone of 
jeopardy. No attempt was made to examine dogs at later 
periods of time. Most studies that have demonstrated the 
greatest improvement in myocardial salvage with hyperos-
molar mannitol (19,31,32) were performed after brief pe-
riods of coronary occlusion followed by reperfusion. In 
animals with coronary reperfusion, mannitol would mini-
mize edema in the ischemic bed, thus improving flow to 
more potentially viable muscle than occurred in the current 
study. Finally, it should be pointed out that antiinflammatory 
agents have been demonstrated to alter healing of myo-
cardial infarcts (33,35) and result in myocardial infarct thin-
ning and elongation. Disruption in scar formation may have 
contributed to the infarct size reduction (as estimated by 
comparison with the initial perfusion defect) produced by 
methylprednisolone. 
From the wet weight-dry weight data derivedfrom studv 
2, it appeared that the reduction in infarct size (or infarct 
jeopardy zone) 4 days after coronary occlusion was signif-
icantly related to a reduction in the water content in the 
infarct segment in the methylprednisolone- and mannitol-
treated dogs. This was not the entire effect. as eventual 
infarct size reduction occurred though infarct water content 
was similar to that in control myocardium. In a study of 4 
and 28 day old infarcts, Reimer and Jennings (36) noted 
that early enlargement (4 days) of infarct volume was sec-
ondary to edema formation, hemorrhage and cellular infil-
tration. We also observed that the volume of the infarct 
progressively diminished in size after 4 days. Carlson et al. 
(37) found a similar pattern of infarct shrinkage at 3 to 4 
weeks. 
Conclusion. Computed tomography is an accurate tech-
nique for measuring and monitoring changes in myocardial 
infarct size and left ventricular muscle mass over time. In 
particular, its ability to determine the effects of drugs on 
infarct size and compensatory increases in left ventricular 
muscle mass may prove clinically important in denning high 
and low risk patient groups. Although caution is advised in 
the clinical application of our results, it is apparent that 
studies designed to show long-term reduction of infarct size 
must take into account the natural and somewhat variable 
regression of quantitative infarct size. 
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